Stocks making the biggest moves midday: Oracle, AST SpaceMobile, Revolution Medicines and more

Equity markets saw varied movements midday, driven by a mix of earnings reports, analyst actions, and specific business developments. American Express surged 6% on strong Q3 results and raised guidance, while AppFolio gained 7% following a KeyBanc upgrade. Conversely, AST SpaceMobile dropped 6% after a Barclays double downgrade, and Micron Technology fell 2% on reports of exiting China's server chip market. State Street and Bank OZK declined after reporting mixed or missed quarterly earnings, while pharmaceutical giants Novo Nordisk and Eli Lilly lost ground following comments on potential obesity drug price reductions, even as regional banks like Zions and Truist Financial generally rebounded.

Analysis

American Express (AXP) surged 6% after reporting Q3 earnings of $4.14 per share on $18.43 billion in revenue, exceeding analyst expectations of $4.00 and $18.05 billion, respectively, and raising full-year guidance. AppFolio (APPF) climbed 7% following a KeyBanc upgrade to overweight with a $285 price target, indicating strong analyst confidence. Regional banks also showed resilience, with Zions (ZION) rallying 4% on a Baird upgrade and Truist Financial (TFC) gaining 3.5% after beating Q3 earnings forecasts.

Conversely, AST SpaceMobile (ASTS) dropped 6% after a Barclays double downgrade to underweight, despite recent significant gains. Micron Technology (MU) fell 2% on reports of exiting China's server chip business due to a prior ban, signaling ongoing geopolitical and market access challenges. State Street (STT) declined over 3% due to mixed Q3 results, as net interest income of $715 million missed the $740.2 million estimate despite overall earnings and revenue beats.

The pharmaceutical sector saw Novo Nordisk (NVO) and Eli Lilly (LLY) lose 3-4% following political comments regarding potential obesity drug cost reductions, introducing regulatory uncertainty. Interactive Brokers (IBKR) fell 3% despite beating Q3 earnings, suggesting strong performance may have been priced in. Oracle (ORCL) shed 7%, giving back gains despite confirming a cloud deal with Meta, potentially indicating profit-taking or concerns over deal specifics.

Key Decisions for Investors

• Investors should monitor regulatory developments impacting pharmaceutical pricing, particularly for GLP-1 medications, and assess the long-term implications for NVO and LLY.
• Evaluate regional bank stability and potential for further upgrades, considering the varied Q3 performances and analyst actions for ZION, TFC, and OZK.
• Reassess technology exposure, especially for companies with significant China market exposure like MU, and consider whether positive earnings surprises, as seen with IBKR, are fully reflected in current valuations.